- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07308132
비호지킨 림프종 환자를 대상으로 한 JNJ-95566692 연구
B-세포 비호지킨 림프종(NHL)에서의 새로운 CD79bxCD20xCD3 삼중특이항체에 대한 1상, 최초 인체 시험
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Edegem, 벨기에, 2650
- 모병
- UZ Antwerpen
-
Liège, 벨기에, 4000
- 모병
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
-
-
-
-
Barcelona, 스페인, 8036
- 모병
- Hosp. Clinic de Barcelona
-
Barcelona, 스페인, 08035
- 모병
- Hosp Univ Vall D Hebron
-
Madrid, 스페인, 28041
- 모병
- Hosp. Univ. 12 de Octubre
-
Madrid, 스페인, 28040
- 모병
- Hosp Univ Fund Jimenez Diaz
-
Madrid, 스페인, 28050
- 모병
- Hosp Univ Hm Sanchinarro
-
-
-
-
-
Ankara, 터키 (Türkiye), 06200
- 모병
- SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
-
Ankara, 터키 (Türkiye), 06620
- 모병
- Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
-
Antalya, 터키 (Türkiye), 07025
- 모병
- Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
-
Istanbul, 터키 (Türkiye), 34010
- 모병
- Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
-
-
-
-
-
Lille, 프랑스, 59000
- 모병
- Hopital Claude Huriez
-
Paris, 프랑스, 75013
- 모병
- CHU Pitie Salpetriere
-
Pierre-Bénite, 프랑스, 69495
- 모병
- CHU Lyon Sud
-
Toulouse, 프랑스, 31100
- 모병
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
-
-
-
Clayton, 호주, 3168
- 모병
- Monash Medical Centre
-
Melbourne, 호주, 3000
- 모병
- Peter MacCallum Cancer Centre
-
North Ryde, 호주, 2109
- 모병
- Macquarie University Hospital
-
Randwick, 호주, 2031
- 모병
- Scientia Clinical Research
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 and no other approved therapies available that would be more appropriate in the investigator's judgment. -Histologic documentation of the following large B-cell lymphomas: -diffuse large B-cell lymphoma not otherwise specified (NOS), -T-cell/histiocyte-rich large B-cell lymphoma, -diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements, -large B-cell lymphoma with IRF4 rearrangement, -high grade B-cell lymphoma with 11q aberrations, -Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma, -diffuse large B-cell lymphoma associated with chronic inflammation, -primary large B-cell lymphoma of immune privileged sites, -primary cutaneous diffuse large B-cell lymphoma-leg type , -primary mediastinal large B-cell lymphoma, -high-grade B-cell lymphoma NOS, -transformations of indolent B-cell lymphoma (For US sites). -Other B-cell NHL may be enrolled based on emerging data in specific cohorts as stipulated by study evaluation team (SET)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
- While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom; -Participants of childbearing potential must have a negative highly sensitive (for example, beta [β]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests, -For Arm E ONLY: Practice 2 methods of reliable birth control simultaneously, including 1 highly effective form of contraception and 1 additional effective contraceptive method., -Participants on Arms C-G should also follow the pregnancy and contraception restrictions in the respective local corresponding product label
Exclusion Criteria:
- Known active central nervous system involvement (CNS) or leptomeningeal involvement
- Prior solid-organ transplantation
- Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment
- Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade <=2 endocrinopathies that are stable on hormone replacement)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: JNJ-95566692
Participants will receive escalating doses of JNJ-95566692 in Part 1 (Dose escalation) to determine the putative recommended Phase 2 doses (RP2D[s]) and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK (pharmacokinetic), pharmacodynamic (PD) and clinical activity. |
JNJ-95566692 will be administered subcutaneously. |
|
실험적: Arm B: JNJ-95566692 in combination with JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 in combination with JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 in combination with JNJ-87801493 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK, PD and clinical activity. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. |
|
실험적: Arm C: JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493
Participants will receive escalating doses for JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Loncastuximab tesirine will be administered intervenously. |
|
실험적: Arm D: JNJ-95566692 and R-GemOx with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and R-GemOx (rituximab, gemcitabine, oxaliplatin) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-GemOx with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Gemcitabine will be administered intravenously. Oxaliplatin will be administered intravenously. |
|
실험적: Arm E: JNJ-95566692 and lenalidomide with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and lenalidomide with or without JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and lenalidomide with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Lenalidomide will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. |
|
실험적: Arm F: JNJ-95566692 and R-CHOP with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-CHOP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Cyclophosphamide will be administered intravenously. Prednisone will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Doxorubicin will be administered intravenously. Vincristine will be administered intravenously. |
|
실험적: Arm G: JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493
Participants will receive escalating doses of JNJ-95566692 and Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1. |
Cyclophosphamide will be administered intravenously. Prednisone will be administered orally. JNJ-87801493 will be administered subcutaneously. JNJ-95566692 will be administered subcutaneously. Rituximab will be administered intravenously and may be administered subcutaneously after the first administration. Doxorubicin will be administered intravenously. Polatuzumab vedotin will be administered intravenously. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity
기간: Approximately 2 years and 8 months
|
An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity for AEs will be specified as per: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades which are Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (potentially life-threatening) and Grade 5 (death related to adverse event). SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
Approximately 2 years and 8 months
|
|
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
기간: Approximately 2 years and 8 months
|
Number of participants with DLTs for JNJ-95566692 (arm A), in combination with JNJ-87801493 (arm B) and in arms C to G will be reported. The DLTs are drug-related toxicities and are defined as any of the following: fatal toxicity, high grade non-hematologic toxicity, or hematologic toxicity. |
Approximately 2 years and 8 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serum Concentration for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
Serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be assessed using a validated assay method. |
Approximately 2 years and 8 months
|
|
Area Under the Curve During a Dosing Interval (AUCtau) in JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
AUC tau is defined as area under the serum concentration-time curve during a dosing interval (tau). |
Approximately 2 years and 8 months
|
|
Maximum Serum Concentration (Cmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
Cmax for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Minimum Serum Concentration (Cmin) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
Cmin for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Area Under the Curve (AUC[0-t]) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
AUC(0-t) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Half-life (t1/2) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
Half-life (t1/2) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Time to Reach Cmax (Tmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
Tmax is the time to reach maximum observed serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Apparent Total Body Clearance (CL/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
CL/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Apparent Volume of Distribution (V/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
기간: Approximately 2 years and 8 months
|
V/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported. |
Approximately 2 years and 8 months
|
|
Number of Participants with Anti-JNJ-95566692 Antibodies in Arms A to G
기간: Approximately 2 years and 8 months
|
Participants with presence of antibodies binding to JNJ-95566692 in arm A to G will be reported. |
Approximately 2 years and 8 months
|
|
Number of Participants with Anti-JNJ-87801493 Antibodies in Arms B to G
기간: Approximately 2 years and 8 months
|
Participants with presence of antibodies binding to JNJ-87801493 in arm B to G (as appropriate) will be reported. |
Approximately 2 years and 8 months
|
|
Part 2: Overall Response for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
기간: Approximately 2 years and 8 months
|
Overall response is defined as a best response of partial response (PR) or better as assessed by the investigator according to standard response criteria per Lugano. |
Approximately 2 years and 8 months
|
|
Part 2: Complete Response (CR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
기간: Approximately 2 years and 8 months
|
Complete response (CR) is defined as a best response of CR as assessed by the investigator according to standard response criteria per Lugano. |
Approximately 2 years and 8 months
|
|
Part 2: Time to Response (TTR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
기간: Approximately 2 years and 8 months
|
TTR is defined for participants who achieved a response of PR or better as the time from the first dose of study treatment to the first response of PR or better. |
Approximately 2 years and 8 months
|
|
Part 2: Duration of Response (DOR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
기간: Approximately 2 years and 8 months
|
DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease, initiation of a new systemic anti-cancer therapy or death. |
Approximately 2 years and 8 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종
- 헴 및 림프병
- 림프종, 비호지킨
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 탄화수소, 순환
- 탄수화물
- 카르 복실 산
- 알칼로이드
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글리코 사이드
- 파이퍼 리딘
- 인돌
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 조정 복합체
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- Pregnadienediols
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 안트라 사이클린
- 나프 타센
- 아미노 글리코 시드
- 항체, 모노클로 날, 뮤린 유래
- Daunorubicin
- 프탈리 미드
- 프탈산
- 산, 카르 보 사이 클릭
- 파이퍼리돈
- Isoindoles
- 레날리도마이드
- 옥살리플라틴
- 리툭시맙
- 젬시타빈
- 프레드니손
- 시클로포스파미드
- 독소루비신
- 빈크리스틴
- 폴라투 주맙 베도틴
- Loncastuximab Tesirine
기타 연구 ID 번호
- 95566692LYM1001
- 95566692LYM1001 (기타 식별자: Janssen Research & Development, LLC)
- 2025-523297-16-00 (레지스트리 식별자: EUCT number)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .